KRAS and colorectal carcinoma: For instance, KRAS-, NRAS, and BRAF-associated mutations in plasma ctDNA of metastatic CRC patients drive primary resistance five to six months post-anti-EGFR regimens like panitumumab and cetuximab [122, 123].